COLLEGE BUSINESS & TECHNOLOGY PARK, DUBLIN 15, L2
Completes Spin-Off of Par Health, Introduces Keenova Therapeutics
Reports Third Quarter 2025 Financial Results
Mallinckrodt plc Changes Fiscal Year End to December 31
Reg. FD
Investor Presentation
Amended material disclosure
Shareholder votes
Q3
Q2
Q1
FY 2024
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus Filed Pursuant to Rule 425
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
S-8 POS
Specialized Disclosure Report